Coronavirus: Chinese firm Zerun Bio to get funding boost for vaccine to protect against all variants
- Global foundation CEPI will invest another US$8.15 million to support phase 1 and 2 trials of the shot as well as a vaccine for the original coronavirus strain
- While existing jabs still offer protection against severe Covid-19 outcomes, new variants such as Delta and Omicron have exposed their limitations
“We must now prioritise development of broadly protective vaccines like the universal influenza vaccines we have been working towards in recent years,” David Morens, Jeffery Taubenberger and Anthony Fauci from the US National Institutes of Health wrote in the New England Journal of Medicine in December.
Scientists at several universities as well as the US military’s Walter Reed Army Institute of Research have been working on so-called pan-coronavirus vaccines.
For its recombinant vaccine candidate, Zerun Bio has made structural changes to the spike protein of the virus – which plays a key role in infecting cells – to improve its ability to trigger an immune response against new coronavirus variants.
Early study results against the original virus have shown the experimental vaccine has a good safety profile and it induced a high level of immune response in adults after two doses, according to a CEPI statement. “The clinical serum demonstrated a good cross-neutralisation effect on Beta and Delta strains,” it said.
In preclinical studies, Zerun Bio’s multi-variant vaccine – being developed using the same technology – also “demonstrated a broad spectrum of cross-neutralisation results” for the Alpha, Beta, Gamma, Delta and Omicron strains.
“Covid-19 continues to evolve, and we cannot predict which path it will take next, so it’s vital that we continue to invest in globally accessible vaccines that are effective against a broad range of possible variants,” said Richard Hatchett, chief executive of CEPI. “Such vaccines can put us a step ahead of the virus, so they are central to the long-term control of Covid-19, and vital to global health security.”
The foundation said the experimental vaccines it was funding, if successful, would be bought and distributed by the Covax Facility, a global initiative to promote equitable access to Covid-19 shots which CEPI co-leads.